Pulmonology

Pulmonology

Pulmonology is the branch of medicine that deals with respiratory diseases.

What are respiratory diseases?

Respiratory diseases affect the tissue and organs that enable us to breathe, including parts of the lung (the alveoli, bronchi, bronchioles, and upper respiratory tract, trachea, pleura and pleural cavity) and nerves and muscles for breathing. This category includes chronic respiratory diseases, such as chronic obstructive pulmonary diseases (COPD) such as chronic bronchitis and emphysema. COPDs drastically impact breathing. Common symptoms include breathlessness, the sensation of feeling the need for air, excessive sputum production, and a chronic cough. The WHO states that 3 million people a year die each year from COPDs. Common risk factors include tobacco smoke, air pollution, occupational chemicals and dusts, and frequent lower respiratory infections during childhood.

Which medicines do we provide for respiratory diseases?

Browse medicines that have been approved for specific respiratory diseases by clicking on a specific disease. If a medicine has been approved by at least one reputable medical authority in the world and is not available in your country, you may be able to purchase it via our service; we may be able to source and deliver it to you if you can provide a prescription from your doctor. 

  1. Orkambi (lumacaftor/ivacaftor)
    Orkambi (lumacaftor/ivacaftor)
    by Vertex Pharmaceuticals (Europe) Ltd
    for Cystic Fibrosis
    €14,490.00
View as Grid List

1 Item

per page
Set Descending Direction

One more step before you can continue

Our service contains information about acquiring medicines that have been approved in another country. This includes professional information such as approval details, product information and pricing. By scrolling, you are declaring that you are requesting any such information.

Scroll down.

No, I'd like to receive general information only.

Disclaimer: The information TSM provides is aimed at patients with terminal and life-debilitating diseases, their doctors and healthcare professionals. It supports an informed decision by the treating doctor about the patient’s treatment and the consideration of a medicine which has not been approved in the patient’s country.